Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis

Многократные введения антител к компоненту сывороточного амилоида P удаляют амилойдные отложения у пациентов с системной амилоидозой
Marianna Fontana, James Moon, Philip N. Hawkins, Mark B. Pepys, Ashutosh Wechalekar, Duncan Richards, Louise Cookson, Sharon V. Barton, Lia Liefaard, Thirusha Lane, David F. Hutt, James M. Ritter, Julian D. Gillmore
2018-01-03
SCID:  54.1/3z456zux Discuss with AI
123I-SAP scintigraphydezamizumab (anti-SAP monoclonal IgG1)miridesap (CPHPC)serum amyloid P component (SAP)systemic amyloidosis
Abstract (AI)
I-SAP scintigraphy confirmed amyloid removal from the spleen and kidneys. No adverse cardiac events attributable to the intervention occurred in the six subjects with cardiac amyloidosis. Amyloid load reduction by miridesap treatment followed by dezamizumab has the potential to improve management and outcome in systemic amyloidosis.
Key Findings
1
123I-SAP scintigraphy confirmed removal of amyloid from spleen and kidneys after treatment.
2
Combination treatment of miridesap to deplete circulating SAP followed by dezamizumab targets residual SAP in amyloid deposits to trigger immunotherapeutic amyloid clearance.
3
Dose-related progressive clearance of hepatic amyloid was observed and was associated with improved liver function tests.
4
No adverse cardiac events attributable to the intervention were observed in six subjects with cardiac amyloidosis.
5
Up to three cycles of miridesap followed by dezamizumab was generally well tolerated in 23 adult systemic amyloidosis patients, with main adverse event being self-limiting early rashes at higher antibody doses.
Research Object

Systemic amyloid deposits in adult patients with systemic amyloidosis treated with miridesap followed by dezamizumab

Research Subject

Dose-related immunotherapeutic clearance of amyloid deposits (amyloid load reduction) measured by SAP and bone-seeking radioligand scintigraphy, MRI extracellular volume, and liver stiffness, and associated safety and pharmacokinetics

Publication Details
Publication Date
2018-01-03
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Marianna Fontana
James Moon
Philip N. Hawkins
Mark B. Pepys
Ashutosh Wechalekar
Duncan Richards
Louise Cookson
Sharon V. Barton
Lia Liefaard
Thirusha Lane
David F. Hutt
James M. Ritter
Julian D. Gillmore
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%